Intravesical epodyl in the management of bladder tumors: combined experience of the Yorkshire Urological Cancer Research Group.
Of 48 patients with bladder tumors treated with intravesical epodyl 17 have shown a complete remission at some stage of treatment, although several have relapsed later. Partial remission occurred in 20 patients and 11 have shown no improvement or the lesions have progressed. Epodyl is used best as an adjunct to transurethral resection or diathermy of T1 bladder lesions. Even in patients who do not show complete remission epodyl may reduce the incidence of recurrence and the number of lesions. It is useful when rapid recurrence of T1 bladder tumors prevents control by resection or diathermy and it also is beneficial as an emergency measure to control hematuria. Complications are not infrequent and may be severe occasionally. Bone marrow depression has been seen in 2 patients whose bladders showed extensive carcinoma in situ.
D000328:Adult; D000368:Aged; D004739:England; D004987:Ethers / Q000008:administration & dosage*; D005009:Ethoglucid / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D012075:Remission, Spontaneous; D001743:Urinary Bladder; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D004987:Ethers; D005009:Ethoglucid